Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

0.1%) infusion bags (advanz pharma - bupivacaine hydrochloride - infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

0.1%) infusion bags (sintetica ltd - bupivacaine hydrochloride - infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

0.125%) infusion bags (sintetica ltd - bupivacaine hydrochloride - infusion - 1.25mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

gedeon richter plc - fluconazole - solution for infusion - 2mg/ml

Canada - English - Health Canada

sanofi-aventis canada inc - avalglucosidase alfa - powder for solution - 100mg - avalglucosidase alfa 100mg - enzymes

Israel - English - Ministry of Health

sanofi israel ltd - avalglucosidase alpha - powder for concentrate for solution for infusion - avalglucosidase alpha 100 mg/vial - avalglucosidase alpha - nexviazyme is indicated long-term enzyme replacement therapy (ert) for the treatment of patients with pompe disease (acid α-glucosidase deficiency)

Kenya - English - Pharmacy and Poisons Board

flucanazole intravenous infusion 2mg/ml 100ml - infusion - flucanazole intravenous infusion 2mg/ml 100ml - fluconazole

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - calcium chloride, dihydrate, glucose monohydrate, magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate, sodium lactate - solution for peritoneal dialysis - calcium chloride dihydrate 0.184 g/l glucose monohydrate 15 g/l sodium hydrogen carbonate 2.1 g/l sodium lactate 1.68 g/l magnesium chloride hexahydrate 0.051 g/l sodium chloride 5.38 g/l - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - calcium chloride, dihydrate, glucose monohydrate, magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate, sodium lactate - solution for peritoneal dialysis - calcium chloride dihydrate 0.184 g/l glucose monohydrate 25 g/l magnesium chloride hexahydrate 0.051 g/l sodium chloride 5.38 g/l sodium hydrogen carbonate 2.1 g/l sodium lactate 1.68 g/l - blood substitutes and perfusion solutions